News - UCB

Filter

Current filters:

UCB

Popular Filters

20 to 44 of 65 results

New study shows UCB's Neupro reduces NSBP in RLS patient

17-05-2013

Leading Belgian drugmaker UCB (Euronext Brussels: UCB) today (May 17) announced data from a double-blind,…

Cardio-vascularNeuproPharmaceuticalResearchUCB

Switch to anabolics driving osteoporosis market growth

11-03-2013

A major paradigm shift in late and mid-stage product development from anti-resorptive therapies to anabolic…

AmgenAnti-Arthritics/RheumaticsMarkets & MarketingPharmaceuticalromosozumabUCB

UCB licenses global rights to tozadenant in Parkinson's disease from Biotie

27-02-2013

Finland-based Biotie Therapies (Nasdaq-OMX: BTH1V) says that UCB (Euronext Brussels; UCB), Belgium's…

Biotie TherapiesLicensingNeurologicalPharmaceuticaltozadenantUCB

UCB links with ConfometRX for neuroscience research

24-02-2013

Belgium's largest drugmaker UCB (Euronext Brussels: UCB) has signed a research agreement with California,…

ConfometRXLicensingNeurologicalPharmaceuticalResearchUCB

UCB files for US and EU approval for Cimzia for psoriatic arthritis and axial spondyloarthritis

20-02-2013

Belgium's largest drugmaker, UCB (Euronext Brussels: UCB) says it has made two new regulatory filings…

Anti-Arthritics/RheumaticsCimziaEuropeNorth AmericaPharmaceuticalRegulationUCB

UCB and Amgen not to progress development of romosozumab for fracture healing

13-02-2013

Belgium's leading drugmaker UCB (Euronext Brussels: UCB) and its partner, US biotech giant Amgen (Nasdaq:…

AmgenAnti-Arthritics/RheumaticsBiotechnologyPharmaceuticalResearchromosozumabUCB

Highlights of ACR meeting include new Cimzia, Stelara and Simponi data

13-11-2012

Belgian drugmaker UCB (UCB: BR) presented results for Cimzia (certolizumab pegol), from the Phase III…

Anti-Arthritics/RheumaticsCimziaJohnson & JohnsonPharmaceuticalResearchSimponi InjectionStelara InjectionUCB

UCB reports 5% lift in first nine-month sales

29-10-2012

Belgium's largest pharma company, UCB (UCB: BR), has reported interim results for the first nine months…

FinancialLicensingolokizumabPharmaceuticalUCB

Belgium's UCB enters third research accord with Harvard University

10-10-2012

Belgium's largest drugmaker, UCB (Euronext Brussels: UCB), says it has launched a third collaborative…

ImmunologicalsPharmaceuticalResearchUCB

Belgium's UCB granted EIB financing for CNS R&D program

28-09-2012

The European Investment Bank (EIB) will grant financing to UCB (Euronext Brussels: UCB), Belgium's largest…

EuropeFinancialNeurologicalPharmaceuticalResearchUCB

UCB inaugurates new biotech plant

16-09-2012

In preparation for the growing demand for biological medicines, Belgian drugmaker UCB (Euronext Brussels:…

BiotechnologyEuropePharmaceuticalProductionUCB

Positive Ph IV data for Pfizer and UCB's Toviaz

06-08-2012

Global drugs behemoth Pfizer (NYSE: PFE) has released positive Phase IV study results assessing the efficacy…

Genito-urinaryPfizerPharmaceuticalResearchToviazUCB

UCB first-half 2012 results miss expectations, hit by costs

02-08-2012

Belgian drugmaker UCB posted first-half 2012 financial results, showing that underlying profitability…

FinancialPharmaceuticalUCB

UCB's Neupro re-launched in USA for Parkinson's and RSL

16-07-2012

Belgium drugmaker UCB (Euronext Brussels: UCB) said yesterday that its Neupro (rotigotine transdermal…

Markets & MarketingNeuproNeurologicalNorth AmericaPharmaceuticalUCB

20 to 44 of 65 results

Back to top